Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Progression Independent of Relapse Activity (US/EU)
Marketed DMTs for multiple sclerosis deliver a high level of efficacy in preventing relapses and relapse-associated worsening of disability (RAW). However, MS patients still experience disability…
Epilepsy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Generalized-Onset Seizures (US)
Generalized-onset seizures (GOS) simultaneously affect both sides of the brain and rapidly engage bilaterally distributed networks. Nearly 40% of the diagnosed epilepsy population presents with…
Alzheimer’s Disease – Special Topics – Special Topics: Caregiver Perspectives on Diagnostics and Leqembi in the Treatment of Alzheimer’s Disease (US)
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…
Autism Spectrum Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Autism Spectrum Disorder (US)
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder involving significant social, communication, and behavioral challenges. Behavioral and developmental therapies are the…
Alzheimer’s Disease – Special Topics – Special Topics: Physician Awareness, Perceptions, and Use of Leqembi (US)
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…
